GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start

Withdrawn before enrolling

Conditions studied: Carcinoma, Hepatocellular

In brief

This study is an international prospective, open-label, multi-center, non-interventional study. The protocol will allow enrollment of all patients with diagnosis of HCC in whom a decision to treat with sorafenib has not been made at time of study enrollment. All patients will be followed-up until withdrawal of consent, lost to follow-up, death, or the end of the study. Detailed information concerning the past medical/surgical history, performance status, methods of diagnosis and staging, etc. of patients with HCC will be collected, and practice patterns of the physicians involved in the care of patients with HCC under real-life conditions will be evaluated.

Key facts

Study ID

NCT01191385

Run by

Bayer

People needed

0

Starts

2010-11-01

Expected to finish

2013-12-01

Last updated by the study team

2017-08-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Outpatients with histologically/cytologically documented or radiographically diagnosed HCC in whom a decision to treat with sorafenib has not been made at this time. Radiographic diagnosis needs typical findings of HCC by radiographic method i.e. on multi-dimensional dynamic CT, CT hepatic arteriography (CTHA)/CT arterial portography (CTAP) or MRI.
• Patients must have signed an informed consent form
• Patients must have a life expectancy of at least 8 weeks

You may not qualify if…

• Patients in whom a decision to treat with sorafenib is made at time of study start
• Patients who have received sorafenib in the past or are currently treated with sorafenib
• Hospice patients

Where it is running

• Study site — Multiple Locations, Arkansas, United States
• Study site — Multiple Locations, California, United States
• Study site — Multiple Locations, Colorado, United States
• Study site — Multiple Locations, District of Columbia, United States
• Study site — Multiple Locations, Florida, United States
• Study site — Multiple Locations, Georgia, United States
• Study site — Multiple Locations, Illinois, United States
• Study site — Multiple Locations, Indiana, United States
• Study site — Multiple Locations, Iowa, United States
• Study site — Multiple Locations, Kentucky, United States
• Study site — Multiple Locations, Louisiana, United States
• Study site — Multiple Locations, Maryland, United States
• Study site — Multiple Locations, Massachusetts, United States
• Study site — Multiple Locations, Michigan, United States
• Study site — Multiple Locations, Minnesota, United States
• Study site — Multiple Locations, Missouri, United States
• Study site — Multiple Locations, New Hampshire, United States
• Study site — Multiple Locations, New Jersey, United States
• Study site — Multiple Locations, New York, United States
• Study site — Multiple Locations, Oregon, United States
• Study site — Multiple Locations, Pennsylvania, United States
• Study site — Multiple Locations, South Carolina, United States
• Study site — Multiple Locations, Texas, United States
• Study site — Multiple Locations, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.